Literature DB >> 33777184

A Critical Overview of Systematic Reviews of Shenfu Injection for Heart Failure.

Jinke Huang1, Yanlu Wang2, Suihe Huang3, Xiaohui Qin4, Fang Yan3, Min Shen1, Yong Huang5.   

Abstract

OBJECTIVES: Shenfu Injection (SFI) was widely used in the treatment of heart failure (HF) in China. A plethora of systematic reviews/meta-analyses (SRs/MAs) has been conducted in this research area, although with scattered results. The purpose of this overview was to conduct a comprehensive review to summarize and critically evaluate the existing evidence.
METHODS: Digital databases were searched for SRs/MAs up to January 28, 2021. Two authors independently screened the reviews and assessed the methodological quality of included SRs/MAs using Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2). Quality of evidence for outcomes evaluated within the reviews was appraised with the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE).
RESULTS: Thirteen SRs/MAs met the inclusion criteria. Based on AMSTAR-2, the quality of all SRs/MAs was critically low, because all of them have more than one critical domains that were unmet. Based on GRADE, the evidence quality of 24 outcome measures was low or very low, 27 outcome measures was moderate, and none outcome measure was high. Descriptive analysis showed that SFI was an effective and safe method for HF.
CONCLUSIONS: The use of SFI for the treatment of HF may be clinically effective and safe. However, this conclusion must be interpreted cautiously due to the generally low methodological quality and low evidence quality of the included SRs/MAs. More rigorously designed SRs/MAs and RCTs with high methodological quality are necessary for further proof.
Copyright © 2021 Jinke Huang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33777184      PMCID: PMC7960068          DOI: 10.1155/2021/8816590

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  11 in total

1.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

Review 2.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  Int J Surg       Date:  2011-10-12       Impact factor: 6.071

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  GRADE guidelines: 3. Rating the quality of evidence.

Authors:  Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

5.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

6.  The skills and experience of GRADE methodologists can be assessed with a simple tool.

Authors:  Susan L Norris; Joerg J Meerpohl; Elie A Akl; Holger J Schünemann; Gerald Gartlehner; Yaolong Chen; Craig Whittington
Journal:  J Clin Epidemiol       Date:  2016-07-14       Impact factor: 6.437

7.  Why prospective registration of systematic reviews makes sense.

Authors:  Lesley Stewart; David Moher; Paul Shekelle
Journal:  Syst Rev       Date:  2012-02-09

8.  Chinese medicine shenfu injection for heart failure: a systematic review and meta-analysis.

Authors:  Song Wen-Ting; Cheng Fa-Feng; Xu Li; Lin Cheng-Ren; Liu Jian-Xun
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-24       Impact factor: 2.629

9.  AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.

Authors:  Beverley J Shea; Barnaby C Reeves; George Wells; Micere Thuku; Candyce Hamel; Julian Moran; David Moher; Peter Tugwell; Vivian Welch; Elizabeth Kristjansson; David A Henry
Journal:  BMJ       Date:  2017-09-21

10.  Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro.

Authors:  Jinqiang Zhu; Wanshan Song; Shixin Xu; Yan Ma; Baoyu Wei; Hongwu Wang; Shengyu Hua
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

View more
  2 in total

1.  Scientific Evidence of Xuebijing Injection in the Treatment of Sepsis.

Authors:  Sa Tian; Defang Qin; Yixuan Ye; Huawei Yang; Shuguang Chen; Tao Liu; Luming Hu; Huiming Li; Qian Niu; Xingzhan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-25       Impact factor: 2.629

2.  Effects of Shenfu injection on inflammatory factors and immune function in children with Mycoplasma pneumoniae: A protocol for a double-blind, randomized controlled trial.

Authors:  Honglian Pei; Youfeng Ma; Lin Wang; Liping Wang; Li Xu; Rong Wang
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.